A nasal powder for hypoglycemia, new cancer biosimilar & 2 more recent FDA approvals

Alia Paavola - Print  | 

Four drugs or medical devices approved by the FDA since July 19:

1. Baqsimi is a nasal powder for severe hypoglycemia, which occurs when a patient's blood sugar falls to a dangerously low level. It usually happens in people who have diabetes. It is the first emergency treatment that can be administered without an injection. 

2. Hadlima is a biosimilar to AbbVie's blockbuster rheumatoid arthritis treatment Humira. It won't be available in the U.S. until June 2023.

3. Ruxience is a biosimilar to Rituxan, a treatment for Non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.  

4. The FDA has approved several new generics of Lyrica, a brand-name drug manufactured by Pfizer to treat fibromyalgia, nerve pain and partial onset seizures in patients 17 years of age and older. They are the first FDA-approved generics for the drug, pregabalin.

More articles on pharmacy:
9 recent drug, device recalls
Owens Healthcare to sell 12 retail pharmacies to CVS
The pharmacies that received the most opioids in every state

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.